AI Engines For more Details: Perplexity Kagi Labs You
Adverse Reactions: Like other anthelmintic medications, parbendazole may cause adverse reactions in humans, including gastrointestinal symptoms such as nausea, vomiting, abdominal pain, and diarrhea. These symptoms may occur as a result of the drug's effects on the parasites and the host's immune response.
Neurotoxicity: Some benzimidazole anthelmintics have been associated with neurotoxic effects, particularly with prolonged or high-dose exposure. Neurological symptoms such as headache, dizziness, confusion, and seizures may occur in rare cases.
Hepatotoxicity: There have been reports of liver toxicity associated with benzimidazole anthelmintics, although this is rare. Liver function tests may be monitored in individuals receiving these medications for extended periods.
Allergic Reactions: Some individuals may experience allergic reactions to parbendazole, which can manifest as skin rash, itching, swelling, or difficulty breathing. These reactions require immediate medical attention.
Drug Interactions: Parbendazole may interact with other medications, particularly those metabolized by the liver. It's important to inform your healthcare provider about all medications, supplements, and herbal products you are taking to avoid potential interactions.
Pregnancy and Breastfeeding: The safety of parbendazole during pregnancy and breastfeeding has not been established. Due to the lack of data on its use in humans and the potential risks to the fetus or infant, parbendazole is generally not recommended for use in pregnant or breastfeeding women.
Resistance: Like other anthelmintic medications, the prolonged or indiscriminate use of parbendazole can contribute to the development of drug-resistant parasites. This can pose challenges in the treatment and control of parasitic infections in both animals and humans.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 2.2 | 0.3 | 6.33 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.6 | 0.6 | 3.33 |
| Allergies | 3.7 | 2.3 | 0.61 |
| Allergy to milk products | 1.4 | 1.3 | 0.08 |
| Alopecia (Hair Loss) | 0.7 | 0.7 | |
| Alzheimer's disease | 3.7 | 5.2 | -0.41 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.7 | 0.6 | 1.83 |
| Ankylosing spondylitis | 3.1 | 1.2 | 1.58 |
| Anorexia Nervosa | 1.4 | 2.6 | -0.86 |
| Antiphospholipid syndrome (APS) | 1.2 | 1.2 | |
| Asthma | 3.4 | 1.1 | 2.09 |
| Atherosclerosis | 1.4 | 1.3 | 0.08 |
| Atrial fibrillation | 3.1 | 2.5 | 0.24 |
| Autism | 6 | 6 | 0 |
| Autoimmune Disease | 0.9 | 0.7 | 0.29 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.3 | 1.3 | |
| Bipolar Disorder | 1.8 | 1.1 | 0.64 |
| Brain Trauma | 0.3 | 1.1 | -2.67 |
| Breast Cancer | 0.9 | 0.9 | |
| Cancer (General) | 0.3 | 0.8 | -1.67 |
| Carcinoma | 3.5 | 1.7 | 1.06 |
| Celiac Disease | 1.7 | 2 | -0.18 |
| Cerebral Palsy | 0.8 | 1.3 | -0.63 |
| Chronic Fatigue Syndrome | 2.6 | 3.9 | -0.5 |
| Chronic Kidney Disease | 2.5 | 2.3 | 0.09 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.4 | 1.7 | -0.21 |
| Chronic Urticaria (Hives) | 1.4 | 0.9 | 0.56 |
| Coagulation / Micro clot triggering bacteria | 1.7 | 1.3 | 0.31 |
| Cognitive Function | 2.5 | 1 | 1.5 |
| Colorectal Cancer | 4.8 | 1.7 | 1.82 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 1.9 | 2.1 | -0.11 |
| COVID-19 | 4.3 | 6.7 | -0.56 |
| Crohn's Disease | 5.3 | 4 | 0.32 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.9 | 1 | -0.11 |
| d-lactic acidosis (one form of brain fog) | 0.3 | 0.3 | |
| deep vein thrombosis | 2 | 1.4 | 0.43 |
| Denture Wearers Oral Shifts | 1.1 | 1.1 | |
| Depression | 5.1 | 6 | -0.18 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 1.4 | 0.9 | 0.56 |
| Endometriosis | 2.9 | 1.8 | 0.61 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 2.7 | 1 | 1.7 |
| erectile dysfunction | 1.4 | 1.4 | |
| Fibromyalgia | 2 | 1.5 | 0.33 |
| Functional constipation / chronic idiopathic constipation | 3.8 | 3.6 | 0.06 |
| gallstone disease (gsd) | 2.9 | 0.8 | 2.62 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.1 | 1.2 | -0.09 |
| Generalized anxiety disorder | 2.3 | 1.1 | 1.09 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.9 | 0.5 | 0.8 |
| Graves' disease | 1 | 2.4 | -1.4 |
| Gulf War Syndrome | 0.9 | 0.2 | 3.5 |
| Halitosis | 1.5 | 0.3 | 4 |
| Hashimoto's thyroiditis | 3 | 1.2 | 1.5 |
| Heart Failure | 3.4 | 1.6 | 1.13 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| High Histamine/low DAO | 1.7 | 0.3 | 4.67 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
| hyperglycemia | 1.2 | 0.9 | 0.33 |
| hypersomnia | 0.1 | -0.1 | |
| hypertension (High Blood Pressure | 3.7 | 2.1 | 0.76 |
| Hypothyroidism | 0.4 | -0.4 | |
| Hypoxia | 3 | 3 | |
| IgA nephropathy (IgAN) | 1.6 | 1.6 | 0 |
| Inflammatory Bowel Disease | 4.1 | 6.5 | -0.59 |
| Insomnia | 1.8 | 2.1 | -0.17 |
| Intelligence | 1.2 | 0.6 | 1 |
| Intracranial aneurysms | 1.4 | 0.3 | 3.67 |
| Irritable Bowel Syndrome | 4.7 | 2.7 | 0.74 |
| ischemic stroke | 1.8 | 1.7 | 0.06 |
| Liver Cirrhosis | 5 | 3.1 | 0.61 |
| Long COVID | 2.9 | 4.6 | -0.59 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.6 | 1 | -0.67 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.6 | 1.5 |
| ME/CFS with IBS | 0.5 | 1.7 | -2.4 |
| ME/CFS without IBS | 0.5 | 1.5 | -2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 4.5 | 3.7 | 0.22 |
| Mood Disorders | 4.8 | 4.8 | 0 |
| multiple chemical sensitivity [MCS] | 0.5 | 0.1 | 4 |
| Multiple Sclerosis | 3.7 | 5.2 | -0.41 |
| Multiple system atrophy (MSA) | 0.4 | -0.4 | |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 1.6 | -1.6 | |
| Neuropathy (all types) | 0.4 | 1.6 | -3 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.5 | 3 | 0.5 |
| NonCeliac Gluten Sensitivity | 0.4 | 0.3 | 0.33 |
| Obesity | 6.5 | 4.9 | 0.33 |
| obsessive-compulsive disorder | 3.7 | 3.1 | 0.19 |
| Osteoarthritis | 1.7 | 0.9 | 0.89 |
| Osteoporosis | 1.9 | 1.3 | 0.46 |
| pancreatic cancer | 0.9 | 0.3 | 2 |
| Parkinson's Disease | 5.2 | 6.1 | -0.17 |
| Polycystic ovary syndrome | 4.9 | 2.3 | 1.13 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.1 | 0.4 | -3 |
| primary biliary cholangitis | 0.9 | 0.9 | 0 |
| Primary sclerosing cholangitis | 1.5 | 2 | -0.33 |
| Psoriasis | 2.1 | 2.8 | -0.33 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.2 | 3.1 | 1 |
| Rosacea | 0.9 | 0.7 | 0.29 |
| Schizophrenia | 3.2 | 2.5 | 0.28 |
| scoliosis | 0.6 | 0.3 | 1 |
| Sjögren syndrome | 2.1 | 1.8 | 0.17 |
| Sleep Apnea | 1.9 | 1.6 | 0.19 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.9 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.7 | 1.7 | |
| Stress / posttraumatic stress disorder | 2.7 | 1.6 | 0.69 |
| Systemic Lupus Erythematosus | 2.8 | 1.3 | 1.15 |
| Tic Disorder | 0.6 | 1.2 | -1 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 2.3 | 1.9 | 0.21 |
| Type 2 Diabetes | 4.6 | 4 | 0.15 |
| Ulcerative colitis | 4.6 | 3 | 0.53 |
| Unhealthy Ageing | 3.2 | 1.9 | 0.68 |
| Vitiligo | 1.8 | 0.9 | 1 |
